ReForm Biologics, a pharmaceutical technology company developing an innovative platform to improve biologic formulations, announced that the issuance of US. patent 9,605,051 (the ‘051 patent) for one of its new excipient formulations.
“The new excipient technology in the ‘051 patent enables high concentration formulations and will further enhance ReForm’s innovative platform for viscosity reduction of biotherapeutics. This new patent is a cornerstone of our proprietary technology platform to improve biologic formulations.”
An important application of the technology in this patent, entitled “Viscosity-Reducing Excipient Compounds for Protein Formulations,” covers the use of a new excipient that significantly reduces the viscosity of highly concentrated therapeutic antibody solutions. ReForm believes that viscosity reduction will allow for more effective formulation and preferable delivery of such antibody solutions to patients.
“Many antibody-based therapeutics need to be delivered intravenously due to their high dose requirements and viscosity in solution. Subcutaneous injection of a highly concentrated antibody solution is a preferred route for patients that require frequent and longer term treatment,” said John M. Sorvillo PhD, chief executive officer. “The new excipient technology in the ‘051 patent enables high concentration formulations and will further enhance ReForm’s innovative platform for viscosity reduction of biotherapeutics. This new patent is a cornerstone of our proprietary technology platform to improve biologic formulations.”